Less is more: Antibiotics at the beginning of life

Nat Commun. 2023 Apr 27;14(1):2423. doi: 10.1038/s41467-023-38156-7.

Abstract

Antibiotic exposure at the beginning of life can lead to increased antimicrobial resistance and perturbations of the developing microbiome. Early-life microbiome disruption increases the risks of developing chronic diseases later in life. Fear of missing evolving neonatal sepsis is the key driver for antibiotic overtreatment early in life. Bias (a systemic deviation towards overtreatment) and noise (a random scatter) affect the decision-making process. In this perspective, we advocate for a factual approach quantifying the burden of treatment in relation to the burden of disease balancing antimicrobial stewardship and effective sepsis management.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Antimicrobial Stewardship*
  • Beginning of Human Life
  • Humans
  • Infant, Newborn
  • Neonatal Sepsis* / drug therapy
  • Sepsis* / drug therapy

Substances

  • Anti-Bacterial Agents